Skip to main content
Berry Genomics Co.,Ltd logo

Berry Genomics Co.,Ltd — Investor Relations & Filings

Ticker · 000710 ISIN · CNE000000PN7 Shenzhen Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 2,009 across all filing types
Latest filing 2017-04-11 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 000710

About Berry Genomics Co.,Ltd

https://www.berrygenomics.com

Berry Genomics Co.,Ltd. is a biotechnology enterprise specializing in clinical genomics and genetic testing services. The company focuses on the research, development, and commercialization of genomic technologies for clinical applications. Its core portfolio includes non-invasive prenatal testing (NIPT), utilizing high-throughput sequencing to screen for chromosomal abnormalities. Beyond reproductive health, the company provides genomic solutions for oncology diagnostics, including early cancer screening and companion diagnostics, as well as testing for hereditary diseases. Berry Genomics leverages advanced sequencing platforms and proprietary bioinformatics pipelines to deliver precision medicine tools to healthcare providers and research institutions. The company is recognized for its role in the clinical application of Next-Generation Sequencing (NGS) and its extensive genomic databases used to enhance diagnostic accuracy and therapeutic outcomes.

Recent filings

Filing Released Lang Actions
控股股东股份被冻结的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the freezing of shares held by the controlling shareholder of the company. It details the number of shares frozen and pledged, references a court order, and includes a statement from the shareholder. There is no financial data, no mention of a report being attached or published, and no indication of a meeting or voting results. This is a regulatory announcement about shareholding status and legal actions affecting shares, which fits best under Regulatory Filings (RNS) as it does not fit other more specific categories like Major Shareholding Notification (MRQ) because it focuses on legal freezing rather than ownership threshold changes.
2017-04-11 Chinese
2017年第一季度业绩预告
Earnings Release Classification · 95% confidence The document is a quarterly earnings forecast for the first quarter of 2017, providing estimated net profit and earnings per share figures. It explicitly states that the forecast is unaudited and based on preliminary financial data, with a note that the actual financial data will be disclosed in the official first quarter report. The document is short (625 characters) and serves as an earnings release or earnings forecast rather than a full interim report containing actual financial statements or detailed analysis. Therefore, it fits best under the Earnings Release (ER) category, which covers initial announcements of quarterly financial results or forecasts. Q1 2017
2017-04-11 Chinese
股票交易异常波动公告
Regulatory Filings Classification · 95% confidence The document is a stock trading abnormal fluctuation announcement by Chengdu Tianxing Instrument Co., Ltd. It discusses unusual stock price movements, verification of information, and risk warnings. It does not contain financial statements or detailed financial analysis but rather regulatory disclosure about stock price behavior and related legal matters. The document length is short (1426 characters) and it serves as a regulatory announcement about stock trading conditions and related shareholder information. This fits the category of Regulatory Filings (RNS), which is a fallback for miscellaneous regulatory announcements that do not fit other specific categories.
2017-04-11 Chinese
关于深圳证券交易所2016年报问询函回复的公告
Annual Report Classification · 95% confidence The document is a detailed response to an inquiry letter from the Shenzhen Stock Exchange regarding the company's 2016 annual report. It includes extensive financial data, production and sales analysis, explanations of accounting treatments, and operational details for the fiscal year 2016. The content is comprehensive and covers multiple aspects of the annual report, including financial performance, asset changes, and business strategy. The document length is over 7,000 characters, indicating it is not a brief announcement but a substantive report. The presence of detailed financial tables, explanations of accounting policies, and discussion of business operations aligns with the characteristics of an Annual Report (10-K equivalent). Therefore, the document should be classified as an Annual Report (10-K). FY 2016
2017-03-30 Chinese
中国证监会行政许可项目审查二次反馈意见通知书
Capital/Financing Update Classification · 95% confidence The document is a notice from the China Securities Regulatory Commission (CSRC) regarding the administrative licensing review of Chengdu Tianxing Instrument Co., Ltd.'s application for approval of issuing shares to purchase assets. It contains detailed feedback and requests for written explanations related to the company's asset purchase and share issuance application. The content focuses on regulatory review comments and requests for supplementary disclosures and opinions from financial advisors and lawyers. The document is not a financial report, earnings release, or management discussion, but rather a regulatory feedback notice related to a capital market transaction approval process. It does not contain financial statements or results but is part of the regulatory filing process for a capital/financing activity. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length is short and does not indicate it is an announcement of a report publication, so it is not RPA or RNS. Confidence is high due to clear regulatory context and content focus on share issuance and asset purchase approval.
2017-03-22 Chinese
关于收到中国证监会行政许可项目审查二次反馈意见通知书的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement from Chengdu Tianxing Instrument Co., Ltd. regarding receipt of a second feedback notice from the China Securities Regulatory Commission (CSRC) about their administrative licensing project review related to a major asset restructuring. It states the company will respond within 30 working days and that the approval is still uncertain. The document is short (631 characters) and serves as a regulatory update on the status of a regulatory approval process, not a full report or financial statement. It does not contain financial data or detailed report content but is an official regulatory announcement. Therefore, it fits best under Regulatory Filings (RNS).
2017-03-22 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.